Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Consensus Rating of “Hold” by Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned a consensus recommendation of “Hold” from the eleven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and six have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $25.6250.

A number of equities analysts recently weighed in on JSPR shares. BTIG Research decreased their price objective on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Evercore ISI reduced their price target on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a research report on Monday, September 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Wednesday, October 8th. William Blair restated a “market perform” rating on shares of Jasper Therapeutics in a report on Monday, July 7th. Finally, Cantor Fitzgerald cut shares of Jasper Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, July 7th.

Jasper Therapeutics Stock Performance

Shares of NASDAQ:JSPR opened at $2.28 on Tuesday. Jasper Therapeutics has a 52-week low of $2.16 and a 52-week high of $26.05. The firm has a fifty day moving average of $2.51 and a 200 day moving average of $3.75. The firm has a market capitalization of $37.06 million, a PE ratio of -0.38 and a beta of 2.79.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.54). On average, sell-side analysts forecast that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

Insider Buying and Selling at Jasper Therapeutics

In other Jasper Therapeutics news, Director Svetlana Lucas purchased 20,000 shares of the business’s stock in a transaction on Monday, September 22nd. The stock was acquired at an average cost of $2.43 per share, for a total transaction of $48,600.00. Following the completion of the transaction, the director directly owned 20,000 shares in the company, valued at approximately $48,600. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Ron Martell acquired 41,000 shares of Jasper Therapeutics stock in a transaction dated Monday, September 22nd. The shares were bought at an average cost of $2.43 per share, for a total transaction of $99,630.00. Following the completion of the purchase, the chief executive officer directly owned 74,118 shares of the company’s stock, valued at approximately $180,106.74. The trade was a 123.80% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 143,000 shares of company stock valued at $347,490. Corporate insiders own 4.60% of the company’s stock.

Hedge Funds Weigh In On Jasper Therapeutics

Large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics in the first quarter valued at approximately $46,000. Marex Group plc purchased a new position in shares of Jasper Therapeutics in the second quarter worth $74,000. Engineers Gate Manager LP bought a new stake in Jasper Therapeutics during the 2nd quarter valued at $78,000. Corton Capital Inc. bought a new stake in Jasper Therapeutics during the 1st quarter valued at $113,000. Finally, XTX Topco Ltd purchased a new stake in Jasper Therapeutics during the 2nd quarter valued at $152,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.